Study of Novel Treatment Combinations in Patients With Lung Cancer
A phase 2 trial of Zimberelimab, Domvanalimab, Sacituzumab govitecan in non-small-cell lung cancer and small-cell lung cancer, run by Gilead Sciences, active and no longer recruiting.
Overview
Study of Novel Treatment Combinations in Patients With Lung Cancer is a phase 2 interventional study registered as NCT05633667 by Gilead Sciences, with 192 participants enrolled, started 2023-03-16 and due to reach its primary completion in 2029-09. Interventions recorded: Zimberelimab (ZIM), Domvanalimab (DOM), Sacituzumab govitecan-hziy (SG), Etrumadenant (ETRUMA), Carboplatin. Conditions listed: Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Cisplatin, Carboplatin.
- TrialStudy Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
Shares Domvanalimab, Zimberelimab, Pemetrexed, Carboplatin.
- TrialStudy of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Subst
Shares Domvanalimab, Zimberelimab, Gilead Sciences (incl. Kite), Carboplatin.
- TrialStudy With Various Immunotherapy Treatments in Participants With Lung Cancer
Shares Domvanalimab, Zimberelimab, Gilead Sciences (incl. Kite), Small-cell lung cancer.
- TrialStudy of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Shares Zimberelimab, Gilead Sciences (incl. Kite), Sacituzumab govitecan, Cisplatin.
- TrialZimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
Shares Domvanalimab, Gilead Sciences (incl. Kite), Non-small-cell lung cancer.
- TrialFirmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
- TrialA Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-S
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.